Article ISI
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER  (2023)

PEMBROLIZUMAB plus CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PATIENTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: BEVACIZUMAB SUBGROUP ANALYSIS BASED ON PROTOCOL-SPECIFIED FINAL OVERALL SURVIVAL RESULTS OF KEYNOTE-826

Lorusso, Domenica; Colombo, Nicoletta; Monk, Bradley J.; Dubot, Coraline; Caceres, Valeria; Hasegawa, Kosei; Shapira-Frommer, Ronnie; Salman, Pamela; Yanez, Eduardo; Gumus, Mahmut; De Mendoza, Mivael Olivera Hurtado; Samouelian, Vanessa; Castonguay, Vincent; Arkhipov, Alexander; Li, Kan; et. al.